UNSPSC 51272002: Thialbarbital

This classification denotes a barbiturate with the molecular formula C13H16N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ENV72C33QD, chemically known as 4,6(1h,5h)-pyrimidinedione, 5-(2-cyclohexen-1-yl)dihydro-5-(2-propenyl)-2-thioxo- (9ci) but generally known as thialbarbital, which bears US NIH Compound Identifier 3032306. European Medicines Agency schedules Thialbarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10966MIG.

UNSPSC 51272002 Thialbarbital is a Commodity code that in recent state and local solicitations actually covers a broad range of pharmaceutical procurement—not thialbarbital specifically, but naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local buying under this code spans county health departments, state HHS agencies, and multistate cooperative purchasing alliances. The work includes both product procurement (naloxone and drug deactivation systems for community health initiatives, generic pharmaceuticals distributed through authorized wholesalers) and exploratory procurement for new pharmacy benefit delivery models. Vendors must meet FDA compliance, Good Manufacturing Practice certification, Drug Supply Chain Security Act requirements, and insurance thresholds including commercial general liability coverage. Cooperative purchasing vehicles appear frequently, with multistate alliances bundling demand across participating jurisdictions to reduce costs and standardize sourcing.

Recent activity spans Florida, Texas, and Minnesota-led multistate regions. Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, including all shipping costs in proposals. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, with pricing evaluated at 75 percent weight and products required available by May 15, 2026 for July 1, 2026 contract effectiveness across participating states including Oregon. The code shows significant activity but is misaligned with its nominal scope—thialbarbital proper does not appear in recent opportunities.